Acetylenic aryl sulfonate hydroxamic acid TACE and matrix...

Details Acetylenic aryl sulfonate hydroxamic acid TACE and matrix... Acetylenic aryl sulfonate hydroxamic acid TACE and matrix...

2007-04-03

2007-04-03

Powers, Fiona T. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C558S058000

Reexamination Certificate

active

10739304

ABSTRACT:
Hydroxamic acids having the formulaare useful in treating disease conditions mediated by TNF-□, such as rheumatoid arthritis, graft rejection, cachexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease or HIV infection.

REFERENCES:
patent: 5455258 (1995-10-01), MacPherson et al.
patent: 5506242 (1996-04-01), MacPherson et al.
patent: 5552419 (1996-09-01), MacPherson et al.
patent: 5753653 (1998-05-01), Bender et al.
patent: 5770624 (1998-06-01), Parker
patent: 5804593 (1998-09-01), Warpehoski et al.
patent: 5817822 (1998-10-01), Nantermet et al.
patent: 5866587 (1999-02-01), De Nanteuil et al.
patent: 5929097 (1999-07-01), Levin et al.
patent: 5962481 (1999-10-01), Levin et al.
patent: 5977408 (1999-11-01), Levin et al.
patent: 6162814 (2000-12-01), Levin et al.
patent: 6162821 (2000-12-01), Levin
patent: 6197795 (2001-03-01), Levin et al.
patent: 6200996 (2001-03-01), Levin et al.
patent: 6207672 (2001-03-01), Thorwart et al.
patent: 6225311 (2001-05-01), Levin et al.
patent: 6228869 (2001-05-01), Levin et al.
patent: 6277885 (2001-08-01), Levin et al.
patent: 6313123 (2001-11-01), Levin et al.
patent: 6326516 (2001-12-01), Levin et al.
patent: 19542189 (1997-05-01), None
patent: 0 606 046 (1994-07-01), None
patent: 0 757 037 (1997-02-01), None
patent: 0 757 984 (1997-02-01), None
patent: 0 803 505 (1997-10-01), None
patent: 0 915 086 (1999-05-01), None
patent: 0 950 656 (1999-10-01), None
patent: WO 95/35275 (1995-12-01), None
patent: WO 95/35276 (1995-12-01), None
patent: WO 96/00214 (1996-01-01), None
patent: WO 96/27583 (1996-09-01), None
patent: WO 96/33172 (1996-10-01), None
patent: WO 97/18194 (1997-05-01), None
patent: WO 97/19068 (1997-05-01), None
patent: WO 97/20824 (1997-06-01), None
patent: WP 97/22587 (1997-06-01), None
patent: WO 97/27174 (1997-07-01), None
patent: WO 97/45402 (1997-12-01), None
patent: WO 98/03166 (1998-01-01), None
patent: WO 98/07697 (1998-02-01), None
patent: WO 98/08815 (1998-03-01), None
patent: WO 98/08822 (1998-03-01), None
patent: WO 98/08823 (1998-03-01), None
patent: WO 98/08825 (1998-03-01), None
patent: WO 98//08827 (1998-03-01), None
patent: WO 98/08853 (1998-03-01), None
patent: WO 98/16503 (1998-04-01), None
patent: WO 98/16506 (1998-04-01), None
patent: WO 98/16514 (1998-04-01), None
patent: WO 98/16520 (1998-04-01), None
patent: WO 98/27069 (1998-06-01), None
patent: WO 98/31664 (1998-07-01), None
patent: WO 98/33768 (1998-08-01), None
patent: WO 98/34918 (1998-08-01), None
patent: WO 98/39313 (1998-09-01), None
patent: WO 98/39315 (1998-09-01), None
patent: WO 98/39329 (1998-09-01), None
patent: WO 98/42659 (1998-10-01), None
patent: WO 98/43963 (1998-10-01), None
patent: WO 99/18074 (1999-04-01), None
patent: WO 00/09492 (2000-02-01), None
patent: WO 00/32570 (2000-06-01), None
patent: WO 00/35885 (2000-06-01), None
patent: WO 00/44709 (2000-08-01), None
patent: WO 00/44710 (2000-08-01), None
patent: WO 00/44711 (2000-08-01), None
patent: WO 00/44713 (2000-08-01), None
patent: WO 00/44716 (2000-08-01), None
patent: WO 00/44723 (2000-08-01), None
patent: WO 00/44730 (2000-08-01), None
patent: WO 00/44740 (2000-08-01), None
patent: WO 00/44749 (2000-08-01), None
patent: WO 00/59285 (2000-10-01), None
patent: WO 01/10827 (2001-02-01), None
patent: WO 01/27084 (2001-04-01), None
Jeremy I. Levin and Mila T. Du; Drug Design and Discovery; vol. 18; No. 4; pp. 123-126, 2003.
International Search Report; Apr. 7, 2005.
Tsuchiya, S., et al., Int. J. Cancer, 26, pp. 171-176, (1980).
Old, Lloyd, J., Science, 230, pp. 630-632, (1985).
Piquet, P.F., et al., J. Exp. Med., 166, pp. 1280-1289, (1987).
Beutler, B., et al., Ann. Rev. Biochem 57, pp. 505-518, (1988).
Mathison, J.C., et al., J. Clin. Invest. 81, pp. 1925-1937 (1988).
Greene, T.W., Wuts, P.G.M., “Protective Groups in Organic Synthesis” 2ndEdition, Wiley & Sons, New York (1991).
Gatanaga, T., et al., Cellular Immunology 138, pp. 1-10, (1991).
Miethke, T., et al., J. Exp. Med. 175, pp. 91-98, (1992).
Peterson, P.K., et al., J. Ciin. Invest. 89, pp. 574-580, (1992).
Hotamisligil, G.S., et al., Science, 259, pp. 87-91, (1993).
Bjornberg, F., et al., Lymphokine Cytokine Res. 13, pp. 203-211, (1994).
Rankin, E.C., et al., Br. J. Rheumatol 34, pp. 334-342, (1995).
Pallares-Trujillo, J., et al., Med. Res. Reviews 15(6), pp. 533-546, (1995).
Ferrari, R., et al., Circulation 92(6), 1479, pp. 1-12 (1995).
Packer, M., Circulation 92(6), 1379, pp. 1-8, (1995).
McGeehan, Gerard M., et al., Current Pharmaceutical Design 2, pp. 662-667 (1996).
Pharmaprojects, Therapeutic Updates 17 (Oct. ), au197 M2Z, (1996).
MacPherson, L.J., J. Med. Chem 40, pp. 2525-2532, (1997).
Isomaki, P., et al., Ann. Med. 29, pp. 499-507, (1997).
Grossman, J.M., et al., Journal of Women's Health 6(6), pp. 627-638, (1997).
Scrip 2349, pp. 20-21, (1998).
Xue, C.B., et al., J. Med. Chem. 41, pp. 1745-1748, (1998).
Lowe, C., et al., Exp. Opin. Ther. Patents 8, pp. 1309-1322, (1998).
Ksontini, R., et al., Arch. Surg. 133, pp. 558-567, (1998).
Camussi, G., et al., Drugs 55(5), pp. 613-620, (1998).
Shire, M.G., et al., Exp. Opin. Ther. Patents 8(5), pp. 531-544, (1998).
Pikul, S., et al., J. Med. Chem 41, pp. 3568-3571, (1998).
Levin, J.I., et al., Bioorg. Med. Chem. Letters 8, pp. 2657-2662, (1998).
Tamura, Y., et al., J. Med. Chem. 41, pp. 640-649, (1998).
Michaelides, M.R., et al., Curr. Pharm. Design 5, pp. 787-819, (1999).
Barkaanm B., et al., J. Med. Chem. 42, pp. 4890-4908, (1999).
Cherney, R.J., et al., Bioorg. Med. Chem. Lett. 9, pp. 1279-1284, (1999).
Newton, R.C., et al., J. Med. Chem. 42, pp. 2295-2314, (1999).
Nelson, F.C., et al., Exp. Opin. Invest. Drugs 8, pp. 383-392, (1999).
Holms, J., et al., Bioorg. Med. Chem. Lett. 11, pp. 2907-2910, (2001).
Levin, J.I., et al., Bioorg. Med. Chem. Lett. 11, pp. 235-238, (2001).
Levin, J.I., et al., Bioorg. Med. Chem Lett. 11, pp. 239-242, (2001).
Levin, J.I., et al., Bioorg. Med. Chem. Lett. 11, pp. 2189-2192, (2001).
Levin, J.I., et al., Bioorg. Med. Chem. Lett. 11, pp. 2975-2978, (2001).
Skiles, J.W., et al., Curr. Med. Chem. 8, pp. 425-474, (2001).
Rabinowitz, M.H., et al., J. Med. Chem. 44, pp. 4252-4267, (2001).
Xue, C.B., et al., J. Med. Chem. 44, pp. 2636-2660, (2001).
Letavic, M.A., et al., Bioorg. Med. Chem. Lett. 12, pp. 1387-1390, (2002).
Levin, J.I., et al., Bioorg. Med. Chem. Lett. 12, pp. 1199-1202, (2002).
Chen, J.M., et al., Bioorg. Med. Chem. Lett. 12, pp. 1195-1198, (2002).
Duan, J.J., et al., J. Med. Chem. 45, pp. 4954-4957, (2002).
Beck, G., et al., J. Parmacol. Exp. Ther. 302, pp. 390-396, (2002).
Kottirsch, G., et al., J. Med. Chem. 45, pp. 2289-2293, (2002).

Affiliated with

Also associated with

Rating

Acetylenic aryl sulfonate hydroxamic acid TACE and matrix... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Acetylenic aryl sulfonate hydroxamic acid TACE and matrix..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acetylenic aryl sulfonate hydroxamic acid TACE and matrix... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3790854